Tirzepatide

What is Tirzepatide? Tirzepatide is a synthetic peptide engineered to activate two endogenous receptors at once — GLP-1 and GIP — using a single 39-residue backbone. Where older incretin research peptides target one receptor, tirzepatide engages both, which is why it has become a reference compound in metabolic-pathway research.

A two-receptor footprint Researchers studying convergent signalling cascades can perturb both pathways with one compound rather than co-administering two, so the experimental readout reflects the combined activity rather than two single-agonist experiments stitched together. A fatty-acid side chain extends serum half-life, giving a duration of action measured in days.

Quality and verification Solid-phase synthesis at 39 residues is non-trivial, so purity matters: REPRIME's HPLC report shows the main-peak area against related substances explicitly, at ≥99% per batch. Each vial carries a unique REP-XXXX-XXXX-X verification code. Supplied as lyophilized 30 mg and 60 mg vials for laboratory and research use only.